fermt2 Antibody

What is FERMT2 and why is it significant in research?

FERMT2, also known as Kindlin-2, KIND2, or MIG2, is a scaffolding protein containing a FERM domain with 680 amino acid residues and a molecular weight of approximately 77.9 kDa. It is primarily localized in the cytoplasm and is ubiquitously expressed across multiple tissue types. FERMT2 enhances integrin activation mediated by TLN1 and/or TLN2, though it activates integrins only weakly by itself. Its significance stems from its involvement in various biological processes, including cell adhesion, migration, and signaling pathways relevant to cancer progression and neurological disorders .

What are the primary applications for FERMT2 antibodies in research?

FERMT2 antibodies are widely employed in multiple research applications. Western Blot is the most commonly used application, allowing for protein detection and quantification. Other frequent applications include Immunocytochemistry for cellular localization, Immunofluorescence for visualization of protein distribution, and Immunohistochemistry for tissue localization. Additionally, Immunoprecipitation and Co-Immunoprecipitation are utilized for protein isolation and interaction studies, respectively .

What are the optimal conditions for Western blot detection of FERMT2?

For optimal Western blot detection of FERMT2, researchers should consider the following parameters:

Researchers should be aware that up to three different isoforms have been reported for FERMT2, which may result in additional bands on Western blots .

What protocols are recommended for immunohistochemical detection of FERMT2?

For immunohistochemical detection of FERMT2, the following protocol is recommended:

• Fix tissue samples in 10% neutral buffered formalin and embed in paraffin.

• Section tissues at 4-6 μm thickness and mount on positively charged slides.

• Deparaffinize and rehydrate sections through a graded alcohol series.

• Perform antigen retrieval using TE buffer pH 9.0 (alternatively, citrate buffer pH 6.0).

• Block endogenous peroxidase activity with 3% hydrogen peroxide.

• Apply primary FERMT2 antibody at a dilution of 1:50-1:500 (depending on the specific antibody).

• Incubate overnight at 4°C or for 1-2 hours at room temperature.

• Apply appropriate secondary antibody and detection system.

• Counterstain with hematoxylin, dehydrate, and mount.

Human lung cancer tissue has been validated as a positive control for IHC applications with certain FERMT2 antibodies .

How should researchers design siRNA experiments targeting FERMT2?

When designing siRNA experiments to knockdown FERMT2 expression, researchers should consider the following approach:

• Select validated siRNA sequences targeting FERMT2, such as:

  • si-1: CCUUGCUGCUCCGAUUCAA(dT)(dT)

  • si-2: GCCCAGGACUGUAUAGUAA(dT)(dT)

  • si-3: GCUAGAUGACCAGUCUGAA(dT)(dT)

• Include appropriate negative controls (e.g., "UUCUCCGAACGUGUCACGUT").

• Transfect cells at 60-80% confluence according to the transfection reagent manufacturer's protocol.

• Verify knockdown efficiency using Western blot analysis.

• Perform functional assays 48-72 hours post-transfection.

This approach has been successfully employed in studies investigating FERMT2's role in cancer-associated fibroblasts and other cellular contexts .

What common issues might researchers encounter with FERMT2 Western blots?

Researchers may encounter several challenges when performing Western blots for FERMT2:

• Multiple bands: This could reflect the presence of different isoforms or post-translational modifications.

• Weak signal: May require optimization of antibody concentration, incubation times, or antigen retrieval methods.

• High background: Could be addressed by increasing washing steps or adjusting blocking conditions.

• Inconsistent results: May stem from variability in protein extraction efficiency or sample handling.

To address these issues, researchers should verify antibody specificity using positive controls (such as A549 cells) and consider testing different antibody dilutions within the recommended range (1:2000-1:14000) .

How can researchers validate the specificity of FERMT2 antibodies?

Validating FERMT2 antibody specificity should involve multiple approaches:

• Positive controls: Use cell lines or tissues known to express FERMT2 (e.g., A549 cells).

• Negative controls: Employ FERMT2 knockdown/knockout samples generated through siRNA or CRISPR/Cas9 techniques.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to confirm specific binding.

• Multiple antibodies: Test different antibodies targeting distinct epitopes of FERMT2.

• Cross-application validation: Confirm consistent results across multiple detection methods (WB, IHC, IF).

Published literature has documented successful antibody validation through at least 13 knockdown/knockout studies, providing valuable reference points for researchers .

What considerations are important when selecting FERMT2 antibodies for specific applications?

When selecting FERMT2 antibodies for specific applications, researchers should consider:

• Target epitope: Antibodies targeting different regions may perform differently across applications.

• Application validation: Verify the antibody has been validated for your specific application.

• Host species: Consider compatibility with other antibodies in multi-labeling experiments.

• Clonality: Monoclonal antibodies offer higher specificity, while polyclonals may provide stronger signals.

• Citation record: Antibodies with publication history in your application provide greater confidence.

• Species reactivity: Ensure compatibility with your experimental model.

For example, the polyclonal antibody 11453-1-AP has been validated for WB, IHC, IF, IP, and CoIP applications with documented reactivity in human, mouse, and rat samples .

How is FERMT2 implicated in cancer research, particularly regarding the tumor microenvironment?

FERMT2 plays significant roles in cancer progression through multiple mechanisms:

• Fibroblast-FERMT2-EMT-M2 macrophage axis: In gastric cancer, FERMT2 expression in fibroblasts promotes epithelial-mesenchymal transition (EMT) and recruits immunosuppressive M2 macrophages, contributing to the mesenchymal phenotype associated with aggressive disease .

• Integrin signaling modulation: FERMT2 participates in integrin-linked kinase signaling pathways, influencing EMT and thereby affecting tumor progression .

• Clinical correlation: High FERMT2 expression is significantly associated with poor clinical outcomes and is upregulated in patients with advanced disease stages .

• Tumor microenvironment regulation: FERMT2 expression patterns correlate with stromal scores and immune cell infiltration in various cancer types, suggesting a broader role in shaping the tumor microenvironment .

These findings collectively suggest that FERMT2 may represent a promising therapeutic target, particularly in advanced gastric cancer .

What is known about FERMT2's involvement in neurodegenerative diseases?

FERMT2 has been identified as a risk factor for Alzheimer's disease, with emerging evidence indicating its multifaceted roles in neuronal function:

• Axonal growth regulation: FERMT2 has been shown to regulate the growth of axons, potentially influencing neuronal network formation and maintenance.

• Synaptic connectivity: FERMT2 plays a role in the connectivity of synapses, which is critical for proper neuronal communication and may be disrupted in neurodegenerative conditions.

• Long-term potentiation: Research indicates FERMT2 involvement in long-term potentiation, a key process underlying learning and memory formation that is often impaired in neurodegenerative diseases .

Further investigation of these mechanisms may provide insights into potential therapeutic approaches targeting FERMT2 in neurodegenerative disorders.

How can researchers investigate FERMT2 mutations in disease contexts?

The mutational landscape of FERMT2 reveals significant alterations across various cancer types, with particularly high mutation rates in uterine corpus endometrial carcinoma (UCEC), stomach adenocarcinoma (STAD), and lung adenocarcinoma (LUAD), exceeding an alteration frequency of 3%. Researchers investigating FERMT2 mutations should consider:

• Mutation profiling: Analysis identified 88 mutations within amino acids 100-600, including 68 missense, 14 truncating, 5 splice, and 1 fusion mutations .

• Correlation analysis: Examining relationships between FERMT2 mRNA expression patterns, mutation types, and copy number alterations can provide insights into functional consequences .

• Functional validation: Testing the effects of specific mutations on FERMT2's scaffolding function, protein-protein interactions, and downstream signaling pathways.

• Clinical significance assessment: Correlating mutation status with patient outcomes, treatment responses, and disease progression.

These approaches can help elucidate the role of FERMT2 mutations in disease pathogenesis and potentially identify novel therapeutic targets.

What emerging techniques are being applied to study FERMT2 function?

Several cutting-edge techniques are being increasingly applied to investigate FERMT2 function:

• CRISPR/Cas9 genome editing: Enabling precise manipulation of FERMT2 expression and sequence to study its function in various cellular contexts.

• Single-cell RNA sequencing: Providing insights into cell-specific FERMT2 expression patterns within heterogeneous tissues and tumor microenvironments.

• Proteomics approaches: Mass spectrometry-based methods to identify FERMT2 interaction partners and post-translational modifications.

• Patient-derived organoids: Three-dimensional culture systems that recapitulate tissue architecture to study FERMT2 function in more physiologically relevant contexts.

• In vivo imaging: Techniques to visualize FERMT2 dynamics in living cells and organisms.

These approaches offer promising avenues for deeper understanding of FERMT2's diverse biological roles.

How might FERMT2 serve as a therapeutic target in disease?

FERMT2's involvement in multiple disease processes suggests several therapeutic targeting strategies:

• In cancer: Targeting the fibroblast-FERMT2-EMT-M2 macrophage axis could potentially disrupt the mesenchymal phenotype of gastric cancer and other malignancies, reducing invasiveness and immunosuppression .

• In neurodegenerative diseases: Modulating FERMT2's effects on axonal growth, synaptic connectivity, and long-term potentiation might offer neuroprotective benefits .

• Targeting approaches could include:

  • Small molecule inhibitors of FERMT2-protein interactions

  • Antisense oligonucleotides to reduce FERMT2 expression

  • Peptide-based disruption of specific FERMT2 functional domains

  • Antibody-based therapeutics for extracellular targeting

Successful therapeutic development will require deeper understanding of FERMT2's context-specific functions and the consequences of its inhibition in different tissues.